Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsExplore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.
Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.
1.
Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness
2.
Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals
3.
Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.
4.
MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information
5.
For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.
1.
ctDNA in Aggressive B-Cell Lymphoma: Redefining MRD and Prognostic Monitoring
2.
Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options
3.
Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy
4.
Case Study: Advancing Preclinical Oncology Drug Development with Quantitative Systems Pharmacology
5.
Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XIV
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
5.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge